SCHEMBL22967402

SCHEMBL22967402

CCNc1ccc(OCc2cc(F)ccc2Cl)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 6/20 0.44
SLC6A4 P31645 6/20 0.44
KCNH2 Q12809 5/20 0.44
GAA P10253 3/20 0.43
MAPT P10636 2/20 0.43
TP53 P04637 1/20 0.43
MAOB P27338 3/20 0.42
ALDH1A1 P00352 2/20 0.42
KDM4E B2RXH2 1/20 0.42
LMNA P02545 1/20 0.42
PLA2G1B P04054 1/20 0.42
ATG4B Q9Y4P1 1/20 0.42
CACNA1C Q13936 1/20 0.40
RAB9A P51151 1/20 0.40
SGMS2 Q8NHU3 1/20 0.39
ADAMTS4 O75173 1/20 0.39
MMP2 P08253 1/20 0.39
MMP13 P45452 1/20 0.39
MMP14 P50281 1/20 0.39
ADAMTS5 Q9UNA0 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22967586 0.86 CACNA1C (0.53) HTR2ASLC6A4GAAMAPTTP53
SCHEMBL22967403 0.85 HTR2A (0.43) HTR2ASLC6A4KCNH2GAAMAPT
SCHEMBL21340843 0.82 HTR2A (0.41) HTR2ASLC6A4KCNH2GAAMAPT
SCHEMBL22874660 0.81 FFAR1 (0.49) HTR2ASLC6A4KCNH2GAAMAPT
SCHEMBL21340749 0.78 MAOB (0.56) HTR2ASLC6A4KCNH2GAAMAPT
SCHEMBL17514997 0.75 RAB9A (0.41) HTR2ASLC6A4KCNH2GAAMAOB
SCHEMBL14380761 0.75 FFAR1 (0.43) SLC6A4GAAMAPTMAOBALDH1A1
SCHEMBL8184326 0.74 ALDH1A1 (0.48) HTR2ASLC6A4KCNH2MAOBALDH1A1
SCHEMBL5087355 0.72 CACNA1C (0.48) HTR2ASLC6A4KCNH2MAOBCACNA1C
SCHEMBL21340748 0.71 CACNA1C (0.52) HTR2ASLC6A4KCNH2GAAMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11548900-B2 Oxazino-quinazoline and oxazino-quinoline type compound, preparation method and uses thereof BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) 2023-01-10 US disclosed
US-20210040114-A1 OXAZINO-QUINAZOLINE AND OXAZINO-QUINOLINE TYPE COMPOUND, PREPARATION METHOD AND USES THEREOF ACCSALUS BIOSCIENCES LIMITED (VG) 2021-02-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11548900-B2 Oxazino-quinazoline and oxazino-quinoline type compound, preparation method and uses thereof WNK1, WNK2, WNK3 HTR2A 2066/4885SLC6A4 1272/4885KCNH2 670/4885
US-20210040114-A1 OXAZINO-QUINAZOLINE AND OXAZINO-QUINOLINE TYPE COMPOUND, PREPARATION METHOD AND USES THEREOF WNK1, WNK2, WNK3 HTR2A 2066/4885SLC6A4 1272/4885KCNH2 670/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.